IP Library Granted Patent US 10,543,211
Granted Patent B2
US 10,543,211 · App. 16/211,409 · Granted Jan 28, 2020

Methods and compositions for treating diseases and conditions

Inventors: Anthony P. Ford (Palo Alto, CA); Julian Paton (Bristol, GB)
Assignee: Afferent Pharmaceuticals, Inc.
A61K31/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,543,211
App. No.
16/211,409
Granted
Jan 28, 2020
Kind
B2
Abstract

Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.

Claims (26)

1. A method of treating sleep apnea in a subject in need thereof, comprising administering to the subject an effective amount compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is hydrogen or C 1 -C 6 alkyl optionally substituted with one to three substituents independently selected from halogen, nitro, cyano, and hydroxy; and

R 2 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, amino, aminosulfonyl, halo, amido, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 hydroxy, C 1 -C 6 haloalkoxy, nitro, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxyalkyl, C 1 -C 6 hydroxyalkoxy, C 2 -C 6 alkynylalkoxy; C 1 -C 6 alkylsulfonyl, C 6 -C 10 arylsulfonyl, C 1 -C 6 carboxyalkyl, cyano, or C 1 -C 6 alkylcarbonyl.

2. The method of claim 1 , wherein the sleep apnea is central sleep apnea.

3. The method of claim 1 , wherein the sleep apnea is obstructive sleep apnea.

4. The method of claim 1 , wherein the sleep apnea is mixed sleep apnea.

5. The method of claim 1 , wherein the sleep apnea occurs more than about 5 apneic events per hour of sleep.

6. The method of claim 1 , wherein the sleep apnea occurs more than about 15 apneic events per hour of sleep.

7. The method of claim 1 , wherein the sleep apnea occurs more than about 25 apneic events per hour of sleep.

8. The method of claim 1 , wherein the compound of formula (I) is:

or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the compound of formula (I) is a pharmaceutically acceptable salt of:

10. The method of claim 1 , wherein the compound of formula (I) is:

or a pharmaceutically acceptable salt.

11. The method of claim 1 , comprising administering to the subject an effective amount of a compound of formula (I) wherein R 1 is C 1 -C 6 alkyl optionally substituted with one to three halogens, or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , comprising administering to the subject an effective amount of a compound of formula (I) wherein R 1 is C 1 -C 6 alkyl, or a pharmaceutically acceptable salt thereof.

13. A method of treating sleep apnea in a subject in need thereof, comprising administering to the subject an effective amount of the following compound:

or a pharmaceutically acceptable salt thereof.

14. The method of claim 13 , comprising administering to the subject an effective amount of the following compound:

15. The method of claim 13 , wherein the sleep apnea is central sleep apnea.

16. The method of claim 13 , wherein the sleep apnea is obstructive sleep apnea.

17. A method of treating sleep apnea in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutically acceptable salt of:

18. The method of claim 17 , wherein the sleep apnea is central sleep apnea.

19. The method of claim 17 , wherein the sleep apnea is obstructive sleep apnea.

20. The method of claim 17 , wherein the sleep apnea occurs more than about 5 apneic events per hour of sleep.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 17197705 PREVIOUSLY RECORDED AT REEL: 061574 FRAME: 0579. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Dec 1, 2022
From: AFFERENT PHARMACEUTICALS, INC.
To: AFFERENT PHARMACEUTICALS, INC.
Reel/Frame 062036/0001 →
CHANGE OF ADDRESS Recorded Sep 30, 2022
From: AFFERENT PHARMACEUTICALS, INC.
To: AFFERENT PHARMACEUTICALS, INC.
Reel/Frame 061574/0579 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2018
From: FORD, ANTHONY P.; PATON, JULIAN
To: AFFERENT PHARMACEUTICALS, INC.
Reel/Frame 047690/0135 →
Continuity (4)
Division 15323619
Provisional Application 62120643 · Feb 25, 2015
Provisional Application 62020839 · Jul 3, 2014
Related Publication 20190175593A1 · Jun 13, 2019